Literature DB >> 18724387

Inhibition of fatty acid amide hydrolase produces PPAR-alpha-mediated analgesia in a rat model of inflammatory pain.

D R Sagar1, D A Kendall, V Chapman.   

Abstract

BACKGROUND AND
PURPOSE: We have previously demonstrated antinociceptive effects of fatty acid amide hydrolase (FAAH) inhibition that were accompanied by increases in the levels of endocannabinoids (ECs) in the hind paw. Here, the effects of the FAAH inhibitor URB597 (3'-carbamoyl-biphenyl-3-yl-cyclohexylcarbamate) on responses of spinal neurons were studied. EXPERIMENTAL APPROACH: Extracellular single-unit recordings of dorsal horn neurons were made in anaesthetized rats with hind paw inflammation induced by lambda-carrageenan. Effects of intraplantar pre-administration of URB597, or vehicle, on carrageenan-evoked expansion of peripheral receptive fields of spinal neurons and mechanically evoked responses of neurons were studied. The cannabinoid receptor type 1 (CB(1)) antagonist AM251 (N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide) and the peroxisome proliferator-activated receptor (PPAR)-alpha antagonist GW6471 ([(2S)-2-[[(1Z)-1-methyl-3-oxo-3-[4-(trifluoromethyl)phenyl]-1-propenyl]amino]-3-[4-[2-(5-methyl-2-phenyl-4-oxa zolyl)ethoxy]phenyl]propyl]-carbamic acid ethyl ester) were used to investigate the roles of these receptors in mediating the effects of URB597. KEY
RESULTS: URB597 (25 microg in 50 microL) pretreatment significantly inhibited carrageenan-evoked receptive field expansion and this was significantly reversed by co-administration of the PPAR-alpha antagonist but not the CB(1) antagonist. Pretreatment with the PPAR-alpha receptor agonist WY14643 ([[4-chloro-6-[(2,3-dimethylphenyl)amino]-2-pyrimidinyl]thio]acetic acid) also significantly inhibited receptive field expansion. URB597 (25 or 100 microg in 50 microL) had no significant effect on mechanically evoked responses of spinal neurons. CONCLUSIONS AND IMPLICATIONS: URB597 inhibited receptive field expansions but not mechanically evoked responses of spinal neurons in rats with hind paw inflammation. These effects were blocked by PPAR-alpha receptor antagonism. These data support the contention that URB597 exerts its antinociceptive effects by indirect inhibition of sensitization of neuronal responses at least partly through PPAR-alpha activation due to enhanced EC levels.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18724387      PMCID: PMC2607214          DOI: 10.1038/bjp.2008.335

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  47 in total

1.  The peroxisome proliferator-activated receptor alpha activator, Wy14,643, is anti-inflammatory in vivo.

Authors:  Paul Colville-Nash; Dean Willis; Jonathan Papworth; Claire Freemantle; Connie Lam; Gemma Andrews; Derek Willoughby
Journal:  Inflammopharmacology       Date:  2005       Impact factor: 4.473

2.  Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms.

Authors:  Leon Chang; Lin Luo; James A Palmer; Steven Sutton; Sandy J Wilson; Ann J Barbier; James Guy Breitenbucher; Sandra R Chaplan; Michael Webb
Journal:  Br J Pharmacol       Date:  2006-05       Impact factor: 8.739

3.  Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha.

Authors:  Jesse LoVerme; Roberto Russo; Giovanna La Rana; Jin Fu; Jesse Farthing; Giuseppina Mattace-Raso; Rosaria Meli; Andrea Hohmann; Antonio Calignano; Daniele Piomelli
Journal:  J Pharmacol Exp Ther       Date:  2006-09-22       Impact factor: 4.030

4.  Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models.

Authors:  Angelo Jayamanne; Ruth Greenwood; Vanessa A Mitchell; Sevda Aslan; Daniele Piomelli; Christopher W Vaughan
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

5.  Activation of the peroxisome proliferator-activated receptor alpha pathway potentiates interleukin-1 receptor antagonist production in cytokine-treated chondrocytes.

Authors:  Mathias François; Pascal Richette; Lydia Tsagris; Catherine Fitting; Cedric Lemay; Mourad Benallaoua; Khadija Tahiri; Marie-Therese Corvol
Journal:  Arthritis Rheum       Date:  2006-04

Review 6.  Peroxisome proliferator-activated receptors and inflammation.

Authors:  Leonardo A Moraes; Laura Piqueras; David Bishop-Bailey
Journal:  Pharmacol Ther       Date:  2005-09-15       Impact factor: 12.310

7.  Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor gamma independently of cannabinoid receptors 1 and 2.

Authors:  Cheryl E Rockwell; Natasha T Snider; Jerry T Thompson; John P Vanden Heuvel; Norbert E Kaminski
Journal:  Mol Pharmacol       Date:  2006-04-12       Impact factor: 4.436

8.  Inhibitors of fatty acid amide hydrolase reduce carrageenan-induced hind paw inflammation in pentobarbital-treated mice: comparison with indomethacin and possible involvement of cannabinoid receptors.

Authors:  Sandra Holt; Francesca Comelli; Barbara Costa; Christopher J Fowler
Journal:  Br J Pharmacol       Date:  2005-10       Impact factor: 8.739

9.  The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide.

Authors:  Jesse Lo Verme; Jin Fu; Giuseppe Astarita; Giovanna La Rana; Roberto Russo; Antonio Calignano; Daniele Piomelli
Journal:  Mol Pharmacol       Date:  2004-10-01       Impact factor: 4.436

10.  Spinal dorsal horn cell receptive field size is increased in adult rats following neonatal hindpaw skin injury.

Authors:  Carole Torsney; Maria Fitzgerald
Journal:  J Physiol       Date:  2003-05-23       Impact factor: 5.182

View more
  45 in total

1.  PPARα agonists--an emerging concept in the management of neuropathic and visceral pain.

Authors:  Shailendra Kapoor
Journal:  Psychopharmacology (Berl)       Date:  2012-03-30       Impact factor: 4.530

2.  Cannabinoid type-1 receptor reduces pain and neurotoxicity produced by chemotherapy.

Authors:  Iryna A Khasabova; Sergey Khasabov; Justin Paz; Catherine Harding-Rose; Donald A Simone; Virginia S Seybold
Journal:  J Neurosci       Date:  2012-05-16       Impact factor: 6.167

3.  An anatomical and temporal portrait of physiological substrates for fatty acid amide hydrolase.

Authors:  Jonathan Z Long; Melanie LaCava; Xin Jin; Benjamin F Cravatt
Journal:  J Lipid Res       Date:  2010-11-19       Impact factor: 5.922

Review 4.  The endocannabinoid system and pain.

Authors:  Josée Guindon; Andrea G Hohmann
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-12       Impact factor: 4.388

5.  Effects of the fatty acid amide hydrolase inhibitor URB597 on pain-stimulated and pain-depressed behavior in rats.

Authors:  Andrew J Kwilasz; Rehab A Abdullah; Justin L Poklis; Aron H Lichtman; Sidney S Negus
Journal:  Behav Pharmacol       Date:  2014-04       Impact factor: 2.293

Review 6.  Role of ionotropic cannabinoid receptors in peripheral antinociception and antihyperalgesia.

Authors:  Armen N Akopian; Nikita B Ruparel; Nathaniel A Jeske; Amol Patwardhan; Kenneth M Hargreaves
Journal:  Trends Pharmacol Sci       Date:  2008-12-11       Impact factor: 14.819

7.  Brain-Permeant and -Impermeant Inhibitors of Fatty Acid Amide Hydrolase Synergize with the Opioid Analgesic Morphine to Suppress Chemotherapy-Induced Neuropathic Nociception Without Enhancing Effects of Morphine on Gastrointestinal Transit.

Authors:  Richard A Slivicki; Shahin A Saberi; Vishakh Iyer; V Kiran Vemuri; Alexandros Makriyannis; Andrea G Hohmann
Journal:  J Pharmacol Exp Ther       Date:  2018-10-01       Impact factor: 4.030

8.  The fatty acid amide hydrolase inhibitor PF-3845 promotes neuronal survival, attenuates inflammation and improves functional recovery in mice with traumatic brain injury.

Authors:  Flaubert Tchantchou; Laura B Tucker; Amanda H Fu; Rebecca J Bluett; Joseph T McCabe; Sachin Patel; Yumin Zhang
Journal:  Neuropharmacology       Date:  2014-06-14       Impact factor: 5.250

Review 9.  Targeting fatty acid amide hydrolase (FAAH) to treat pain and inflammation.

Authors:  Joel E Schlosburg; Steven G Kinsey; Aron H Lichtman
Journal:  AAPS J       Date:  2009-01-29       Impact factor: 4.009

Review 10.  Dynamic regulation of the endocannabinoid system: implications for analgesia.

Authors:  Devi Rani Sagar; A Gemma Gaw; Bright N Okine; Stephen G Woodhams; Amy Wong; David A Kendall; Victoria Chapman
Journal:  Mol Pain       Date:  2009-10-08       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.